PP
OLMA icon

PDT Partners’s Olema Pharmaceuticals OLMA Stock Holding History

PDT Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,301
Closed -$228K – 579
2026
Q1 		$228K Sell
15,301
-12,067
-44% -$269K 0.01% 486
2025
Q4 		$684K Buy
27,368
+12,067
+79% +$215K 0.04% 381
2025
Q3 		$150K Sell
15,301
-13,036
-46% -$78.3K 0.01% 557
2025
Q2 		$121K Sell
28,337
-45,962
-62% -$205K 0.01% 664
2025
Q1 		$279K Buy
+74,299
New +$374K 0.02% 624
2023
Q2 		– Sell
-10,573
Closed -$36.7K – 633
2023
Q1 		$36.7K Sell
10,573
-12,841
-55% -$52.4K 0.01% 555
2022
Q4 		$57.4K Sell
23,414
-13,127
-36% -$38.3K 0.01% 599
2022
Q3 		$101K Sell
36,541
-55,813
-60% -$237K 0.02% 780
2022
Q2 		$376K Sell
92,354
-30,004
-25% -$95.2K 0.03% 685
2022
Q1 		$521K Buy
122,358
+97,189
+386% +$536K 0.04% 572
2021
Q4 		$236K Buy
+25,169
New +$521K 0.02% 735

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

PDT Partners's OLMA Position: Q2 2026 in Review

PDT Partners sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 15,301 shares — an estimated $228K sold.

PDT Partners first reported a position in OLMA in Q4 2021 and held it in 11 quarters. The position peaked at $684K in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • PDT Partners reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • PDT Partners sold 15,301 Olema Pharmaceuticals shares in Q2 2026, an estimated $228K.
  • PDT Partners first reported a position in Olema Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • PDT Partners's Olema Pharmaceuticals position peaked at $684K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.